Therefore, it is possible that the recognition by 6B1 for HLA-A2–bound phosphopeptides derived from other cancer-associated proteins such as PKD2, which share similar amino acid compositions, might greatly expand the cancer target spectrum, allowing 1 mAb to target a wide array of cancers. This evidence concerns the gene PKD2 and cancer.